Patients in the MBGrp3 with non-MYC amplified tumours were at high risk, with progression-free survival similar to that for the MBGrp4-HR subgroup (51 [91%] of 56 patients; 46% [95% CI 33–64] for MBGrp3 with non-MYC amplified tumours vs 41% [28–60] for MBGrp4-HR). This evidence concerns the gene MYC and neoplasm.